Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | BAX | Q07812 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5274339 | 1.00 | LTA4H (0.41) | LTA4HTSHRCA5ACA5BCA4 | |
| SCHEMBL16782647 | 0.83 | LTA4H (0.50) | LTA4HTSHRCA5ACA5BCA4 | |
| SCHEMBL2818333 | 0.83 | LTA4H (0.50) | LTA4HTSHRCA5ACA5BCA4 | |
| SCHEMBL2818335 | 0.83 | LTA4H (0.50) | LTA4HTSHRCA5ACA5BCA4 | |
| SCHEMBL28749812 | 0.80 | LTA4H (0.39) | LTA4HTSHRCA5ACA5BNR1H2 | |
| SCHEMBL28145862 | 0.80 | ELANE (0.55) | ALDH1A1 | |
| SCHEMBL29108812 | 0.78 | ALDH1A1 (0.50) | ALDH1A1ALOX15LMNA | |
| SCHEMBL1544163 | 0.78 | — | — | |
| SCHEMBL11541783 | 0.78 | LTA4H (0.45) | LTA4HTSHRCA5ACA5BCA4 | |
| SCHEMBL11541789 | 0.78 | LTA4H (0.45) | LTA4HTSHRCA5ACA5BCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160120794-A1 | COMPOUNDS ENCAPSULATED NANOPARTICLES AND NANOEMULSIONS PREPARATION AND USE THEREOF | LIU HUIWEN (US) | 2016-05-05 | — | — | US | claimed |
| WO-2014197008-A1 | COMPOUNDS ENCAPSULATED NANOPARTICLES AND NANOEMULSIONS PREPARATION AND USE THEREOF | LIU HUIWEN (US) | 2014-12-11 | — | — | WO | claimed |
| US-6589514-B2 | Plant extract; skin repair | MORINDA, INC. | 2003-07-08 | — | — | US | claimed |
| US-20020192246-A1 | Morinda citrifolia (Noni) enhanced cosmetic intensive repair serum | MORINDA, INC. | 2002-12-19 | — | — | US | claimed |
| EP-0729342-A1 | FOAMING AGENT FOR LEAVE-ON FOAMING COSMETIC COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1996-09-04 | — | — | EP | claimed |
| WO-1995013788-A1 | FOAMING AGENT FOR LEAVE-ON FOAMING COSMETIC COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1995-05-26 | — | — | WO | claimed |
| US-20260061061-A1 | NON-ACTIVATED, AMORPHOUS, pH NEUTRAL, TWO-PART BEDSIDE-READY CLAY DELIVERY SYSTEM THAT TREATS PATHOGEN INFECTIONS IN HUMANS AND ANIMALS | MCCORD DARLENE E (US) | 2026-03-05 | — | — | US | disclosed |
| US-12478681-B2 | Non-activated, amorphous, pH neutral, two-part bedside-ready clay delivery system that treats pathogen infections in humans and animals | McCord, Darlene E. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20230226108-A1 | NON-ACTIVATED, AMORPHOUS, pH NEUTRAL, TWO-PART BEDSIDE-READY CLAY DELIVERY SYSTEM THAT TREATS PATHOGEN INFECTIONS IN HUMANS AND ANIMALS | MCCORD DARLENE E (US) | 2023-07-20 | — | — | US | disclosed |
| US-11638759-B2 | Non-activated, amorphous, pH neutral, two-part bedside-ready clay delivery system that treats pathogen infections in humans and animals | McCord, Darlene E. (US) | 2023-05-02 | — | — | US | disclosed |
| EP-4013372-A1 | NON-ACTIVATED, AMORPHOUS, PH NEUTRAL, TWO-PART BEDSIDE-READY CLAY DELIVERY SYSTEM THAT TREATS PATHOGEN INFECTIONS IN HUMANS AND ANIMALS | McCord, Darlene E. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11351110-B2 | Silicone-free cosmetic compositions | Thomas, Kirsten Elizabeth (US) | 2022-06-07 | — | — | US | disclosed |
| US-11160765-B2 | Compositions and methods of treating fungal infections of the nails | KBR Incorporated (US) | 2021-11-02 | — | — | US | disclosed |
| US-6589514-B2 | Plant extract; skin repair | MORINDA, INC. | 2003-07-08 | — | — | US | disclosed |
| US-6169110-B1 | COMPRISING A THERAPEUTIC AMOUNT OF VITAMIN A PROPIONATE AND GLYCOLIC ACID IN A PHARMACEUTICALLY ACCEPTABLE CARRIER | VIVANT PHARMACEUTICALS | 2001-01-02 | — | — | US | disclosed |
| WO-1997018804-A1 | REJUVENATING THE SKIN USING A COMBINATION OF VITAMIN A AND ALPHAHYDROXY ACIDS | VIVANTE PHARMACEUTICALS, INC. (US) | 1997-05-29 | — | — | WO | disclosed |
| EP-0729342-A1 | FOAMING AGENT FOR LEAVE-ON FOAMING COSMETIC COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995013788-A1 | FOAMING AGENT FOR LEAVE-ON FOAMING COSMETIC COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1995-05-26 | — | — | WO | disclosed |
| US-4637986-A | LEUKOCYTES, BUFFERS, ALKOXYETHANOL | ORTHO DIAGNOSTIC SYSTEMS, INC. (US) | 1987-01-20 | — | — | US | disclosed |
| EP-0136058-A2 | Flow cytometry lysing reagent with leukoprotective agent for producing a 3-part WBC count | ORTHO DIAGNOSTIC SYSTEMS INC. (US) | 1985-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12478681-B2 | Non-activated, amorphous, pH neutral, two-part bedside-ready clay delivery system that treats pathogen infections in humans and animals | NONO, CUTA, LRBA | LTA4H 395/4885TSHR 3225/4885CA5A 3157/4885 |
| US-20230226108-A1 | NON-ACTIVATED, AMORPHOUS, pH NEUTRAL, TWO-PART BEDSIDE-READY CLAY DELIVERY SYSTEM THAT TREATS PATHOGEN INFECTIONS IN HUMANS AND ANIMALS | NONO, CUTA, LRBA | LTA4H 395/4885TSHR 3225/4885CA5A 3157/4885 |
| US-20260061061-A1 | NON-ACTIVATED, AMORPHOUS, pH NEUTRAL, TWO-PART BEDSIDE-READY CLAY DELIVERY SYSTEM THAT TREATS PATHOGEN INFECTIONS IN HUMANS AND ANIMALS | CUTA, NONO, SLC11A2 | LTA4H 1776/4885TSHR 2165/4885CA5A 3782/4885 |
| US-11638759-B2 | Non-activated, amorphous, pH neutral, two-part bedside-ready clay delivery system that treats pathogen infections in humans and animals | NONO, CUTA, LRBA | LTA4H 395/4885TSHR 3225/4885CA5A 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.